Burns - MultipleREMBRANTNCT07435402
Reduction of Muscle Catabolism Through Brain Activation in Burn Patients
A study testing Burn-Bundle Extended Rehabilitation Program, Isoflurane Inhalational Sedation and Functional Proprioceptive Stimulation in people with Burns - Multiple and Critical Illness, run by Charles University, Czech Republic at 1 site in Czechia.
Trial summary
Patients with extensive burn injuries frequently develop severe skeletal muscle wasting and weakness as part of critical illness-related myopathy and neuropathy. This condition delays ventilator weaning, prolongs intensive care unit (ICU) and hospital stay, and contributes to long-term functional impairment and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Burns - Multiple, Critical Illness, Muscle Weakness
- What is being tested?
- Burn-Bundle Extended Rehabilitation Program, Isoflurane Inhalational Sedation and Functional Proprioceptive Stimulation
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteCzechia
- Study dates
- 1 May 2026to 30 Jun 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older
- Severe burn injury involving more than 30% of total body surface area (TBSA)
- Admission to the intensive care unit
- Expected need for invasive mechanical ventilation and continuous sedation for at least 7 days
- Ability to obtain written informed consent from the patient or a legally authorized representative
Who cannot join
- Pre-existing severe neuromuscular or neurodegenerative disease
- Known contraindication to inhalational sedation with isoflurane
- Pregnancy or breastfeeding
- Participation in another interventional clinical trial that could interfere with the study outcomes
- Any condition that, in the opinion of the investigator, would make participation in the study unsafe or interfere with protocol adherence
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Czechia1 site
University Hospital Královské Vinohrady
Prague, Česká Republika, 100 34
Robert Zajíček, MD, PhD, +420 26716 3392, robert.zajicek@fnkv.cz
Study coordinator, burnsec@fnkv.cz
About this study
Official title: Reduction of Muscle Catabolism Through Brain Activation in Burn Patients (REMBRANT)
Patients with extensive burn injuries frequently develop severe skeletal muscle wasting and weakness as part of critical illness-related myopathy and neuropathy. This condition delays ventilator weaning, prolongs intensive care unit (ICU) and hospital stay, and contributes to long-term functional impairment and reduced quality of life. In burn patients, muscle loss is particularly pronounced during the early post-injury phase and is associated with mitochondrial dysfunction and altered neuromuscular signaling.
Effective strategies to prevent muscle catabolism in critically ill burn patients remain limited. Although early active rehabilitation is beneficial, many patients are unable to participate due to deep sedation, mechanical ventilation, or clinical instability. Therefore, innovative rehabilitation approaches applicable during the acute phase of critical illness are needed.
Read more
The REMBRANT (REduction of Muscle catabolism through BRAin activation in burn patieNTs) study is a single-center, randomized, controlled, open-label clinical trial evaluating whether a multimodal brain-activating rehabilitation strategy can attenuate skeletal muscle loss in adult patients with severe burns. Thirty patients with burns involving more than 30% of total body surface area who require invasive mechanical ventilation and prolonged sedation will be randomized in a 1:1 ratio to standard care or an intervention group.
Both groups will receive standardized burn treatment and conventional rehabilitation. The intervention group will additionally receive the Burn-Bundle Extended Rehabilitation Program, combining inhalational isoflurane sedation with functional proprioceptive stimulation, repetitive transcranial magnetic stimulation, and virtual reality-assisted rehabilitation when clinically feasible.
The primary outcome is change in skeletal muscle mass and strength. Secondary outcomes include ICU length of stay, ventilator-free days, mitochondrial function, and health-related quality of life.
Read the detailed description
Critically ill patients with extensive burn injuries are at exceptionally high risk of developing profound skeletal muscle wasting and weakness as part of critical illness-related myopathy and neuropathy (CRIMYNE). This condition represents a major determinant of short- and long-term outcomes, contributing to delayed ventilator weaning, prolonged intensive care unit (ICU) and hospital length of stay, impaired rehabilitation, and persistent functional disability after discharge. In patients with large burns, muscle loss is particularly rapid and severe during the early post-injury phase, frequently exceeding 1 kg of lean body mass per day, and is accompanied by mitochondrial dysfunction, systemic inflammation, altered myokine signaling, and neurodegenerative changes affecting central, peripheral, and autonomic nervous systems.
Despite extensive research, effective preventive or therapeutic strategies to limit skeletal muscle catabolism in critically ill burn patients remain limited. Nutritional optimization, pharmacological interventions, and passive or assisted rehabilitation techniques have demonstrated minimal or inconsistent benefit. Active rehabilitation remains the only proven preventive approach; however, a substantial proportion of burn patients are unable to participate due to deep sedation, invasive mechanical ventilation, hemodynamic instability, prone positioning, unstable fractures, or the extent and severity of burn injuries. Consequently, there is a critical unmet need for rehabilitation strategies that can be applied safely and effectively during the early acute phase of critical illness.
Recent advances in neurorehabilitation suggest that activation of central motor pathways may exert anti-catabolic effects on skeletal muscle even in immobilized or unconscious patients. Functional proprioceptive stimulation (illusory movements induced by focal muscle vibration) activates cortical motor areas and has been shown to promote antidegenerative processes within the nervous system and skeletal muscle. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique capable of modulating cortical excitability and enhancing neuroplasticity, with established safety and efficacy in various neurological and movement disorders. Virtual reality (VR)-assisted rehabilitation provides immersive multisensory stimulation and may enhance motor network activation and engagement in conscious patients.
Sedation strategy is another critical determinant of neurological and functional outcomes in critically ill patients. Conventional intravenous sedatives, including propofol, dexmedetomidine, and benzodiazepines, are associated with adverse effects such as hemodynamic instability, prolonged awakening, delirium, drug accumulation, and potential neurodegenerative effects. Inhalational sedation with isoflurane represents a validated alternative that allows predictable awakening, preservation of spontaneous breathing, reduced opioid requirements, and potentially improved neurocognitive outcomes. Its use may facilitate daily sedation interruptions and early rehabilitation strategies in ICU patients.
The REMBRANT (REduction of Muscle catabolism through BRAin activation in burn patieNTs) study is a single-center, randomized, controlled, open-label clinical trial designed to evaluate whether a multimodal brain-activating rehabilitation strategy can attenuate skeletal muscle catabolism and improve functional outcomes in adult patients with extensive burn injuries. The study aims to integrate optimized sedation with innovative neurorehabilitation techniques to target the central mechanisms contributing to muscle wasting in critical illness.
A total of 30 adult patients with burns involving more than 30% of total body surface area (TBSA), admitted to the ICU and expected to require invasive mechanical ventilation and continuous sedation for at least seven days, will be enrolled. Participants will be randomized in a 1:1 ratio to either a control group receiving standard care or an intervention group receiving the Burn-Bundle Extended Rehabilitation Program. The study is conducted at a single specialized burn center to ensure standardized implementation of complex interventions and uniform data acquisition.
Both groups will receive standardized burn care and conventional rehabilitation according to institutional protocols. The control group will be sedated using standard intravenous sedatives, including propofol and/or dexmedetomidine. The intervention group will undergo inhalational sedation with isoflurane for the required duration of sedation. In addition, the intervention group will receive the Burn-Bundle Extended Rehabilitation Program, consisting of functional proprioceptive stimulation, repetitive transcranial magnetic stimulation, and virtual reality-assisted rehabilitation when consciousness allows. Functional proprioceptive stimulation will be applied twice daily during the early acute phase after burn injury, while rTMS will be administered once daily to potentiate cortical activation. Virtual reality-based interventions will be introduced in conscious patients as part of semi-active rehabilitation.
The primary objective of the study is to evaluate the effect of the intervention on skeletal muscle quantity and functional status during hospitalization and after discharge. Skeletal muscle mass and body composition will be assessed using dual-energy X-ray absorptiometry (DEXA), ultrasound measurement of the rectus femoris muscle, and anthropometric assessments. Functional status will be evaluated using standardized functional tests, including the Medical Research Council (MRC) sum score.
Secondary objectives include assessment of ICU length of stay, ventilator-free days, cognitive recovery, and quality of life. Quality of life will be evaluated using the EQ-5D-5L questionnaire at discharge and during follow-up visits at 3 and 6 months after hospital discharge. Cognitive recovery will be assessed using standardized clinical evaluations appropriate for critically ill patients.
A key mechanistic component of the study involves detailed metabolic and molecular analyses of skeletal muscle. Muscle biopsies obtained during routine surgical procedures will be used to assess mitochondrial bioenergetics using high-resolution respirometry. Parameters of mitochondrial function, including oxidative phosphorylation capacity, fatty acid oxidation, and respiratory control ratios, will be analyzed to determine the impact of the intervention on muscle energy metabolism.
In parallel, circulating and intramuscular myokine profiles will be analyzed using multiplex immunoassays. Selected myokines involved in muscle metabolism, inflammation, and neuro-muscular signaling will be measured in plasma samples and muscle biopsies at predefined time points during hospitalization. These analyses aim to elucidate the molecular mechanisms underlying muscle catabolism and recovery and to identify potential biomarkers associated with response to rehabilitation.
The study will be conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and applicable local regulatory requirements. Written informed consent will be obtained from all participants or their legally authorized representatives prior to study inclusion. The study protocol has been approved by the local Ethics Committee.
By combining optimized inhalational sedation with innovative neurorehabilitation techniques applicable during the acute phase of critical illness, the REMBRANT study aims to establish a novel therapeutic approach to limit skeletal muscle wasting in critically ill burn patients. The results of this study may provide important insights into central mechanisms of muscle catabolism and recovery and contribute to improved short-term clinical outcomes as well as long-term functional recovery and quality of life in this vulnerable patient population.
- Conditions
- Burns - Multiple, Critical Illness, Muscle Weakness
- Being tested
- Burn-Bundle Extended Rehabilitation Program, Isoflurane Inhalational Sedation, Functional Proprioceptive Stimulation, Neurorehabilitation Techniques
- Keywords
- extensive burn injury, skeletal muscle wasting, brain activation
- Medical subject headings
- Critical Illness, Muscle Weakness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Burn-Bundle Extended Rehabilitation ProgramOther
A multimodal brain-activating rehabilitation program consisting of inhalational isoflurane sedation combined with functional proprioceptive stimulation, repetitive transcranial magnetic stimulation, and virtual reality-assisted rehabilitation when consciousness allows, applied during the acute phase after severe burn injury.
Isoflurane Inhalational SedationDrug
Sedation with inhaled isoflurane administered via an anesthetic conserving device during invasive mechanical ventilation, used as an alternative to standard intravenous sedatives.
Functional Proprioceptive StimulationDevice
Illusory movements induced by focal vibration of muscle attachments to activate central motor pathways, applied twice daily during the acute phase of critical illness.
Neurorehabilitation TechniquesDevice
Non-invasive neurorehabilitation techniques including repetitive transcranial magnetic stimulation and virtual reality-assisted rehabilitation applied to enhance cortical activation and neuroplasticity in critically ill burn patients when clinically feasible.
| Study group | Role | What they receive |
|---|---|---|
| Propofol Group | No intervention | Standard Burn Care with Intravenous Sedation |
| Isoflurane Group | Experimental | Burn-Bundle Extended Rehabilitation Program with Isoflurane Sedation Receives: Other: Burn-Bundle Extended Rehabilitation Program; Drug: Isoflurane Inhalational Sedation; Device: Functional Proprioceptive Stimulation; Device: Neurorehabilitation Techniques |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in skeletal muscle mass assessed by dual-energy X-ray absorptiometry (DEXA)
Change in lean body mass measured by dual-energy X-ray absorptiometry. Lean mass is reported in kilograms (kg).
Measured: From baseline (within first 7 days after ICU admission) up to 24 weeks.
Change in rectus femoris muscle thickness assessed by ultrasound
Change in rectus femoris muscle thickness measured by ultrasound. Muscle thickness is reported in millimeters (mm).
Measured: From baseline (day 10 after injury) to day 30 after injury
Change in muscle strength assessed by the Medical Research Council (MRC) Sum Score
Muscle strength assessed using the Medical Research Council (MRC) Sum Score. The MRC Sum Score ranges from 0 to 60, with higher scores indicating greater muscle strength.
Measured: From baseline (within first 7 days after ICU admission) up to 24 weeks.
Secondary outcomes (8)
Intensive care unit length of stay
Length of stay in the intensive care unit measured in days.
Measured: From ICU admission up to 24 weeks.
Ventilator-free days
Number of days alive and free from invasive mechanical ventilation during the ICU stay.
Measured: From ICU admission up to 24 weeks.
Mitochondrial oxidative phosphorylation capacity
Oxidative phosphorylation capacity measured by high-resolution respirometry in skeletal muscle biopsy samples. Results reported as oxygen flux (pmol O2·s-¹·mg-¹).
Measured: Days 10, 20, and 30 after injury
Myokine profiles
Plasma concentrations of selected myokines measured using multiplex immunoassays. Results reported in pg/mL.
Measured: During hospitalization (days 10, 20, and 30 after injury).
Cognitive function assessed using the Montreal Cognitive Assessment (MoCA). The MoCA score ranges from 0 to 30, with higher scores indicating better cognitive performance.
Cognitive function assessed using the Montreal Cognitive Assessment (MoCA). The MoCA score ranges from 0 to 30, with higher scores indicating better cognitive performance.
Measured: At hospital discharge, 3 months, and 6 months after discharge.
Health-related quality of life assessed by the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L)
Health-related quality of life assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). The EQ-5D-5L index score typically ranges from values below 0 (worse than death) to 1 (full health). Higher scores indicate better health status.
Measured: At hospital discharge, 3 months, and 6 months after discharge
Fatty acid oxidation capacity of skeletal muscle mitochondria
Fatty acid oxidation capacity measured by high-resolution respirometry in skeletal muscle biopsy samples, reported as oxygen flux (pmol O2·s-¹·mg-¹).
Measured: Days 10, 20, and 30 after injury
Mitochondrial respiratory control ratio
Respiratory control ratio calculated as the ratio of ADP-stimulated respiration to resting respiration.
Measured: Days 10, 20, and 30 after injury
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study start1 May 2026 (estimated)
- Primary completion31 Dec 2029 (estimated)
- Study completion30 Jun 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Burns - MultipleStudies of the same condition, open and under way.
- More trials run by Charles University, Czech RepublicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly assigned in a 1:1 ratio to one of two parallel groups: a control group receiving standard burn care and conventional rehabilitation with intravenous sedation, and an intervention group receiving standard burn care plus the Burn-Bundle Extended Rehabilitation Program, including inhalational isoflurane sedation and multimodal neurorehabilitation. Participants will remain in their assigned group for the duration of the study.
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Charles University, Czech Republic
- Sponsor type
- University, hospital or other
- Collaborators
- Masaryk University
- Responsible party
- Sponsor
- Investigators
- Bohumil Bakalář, MD, PhD, Principal investigator, University Hospital Kralovske Vinohrady Praha Czech Republic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07435402
- Sponsor's protocol ID
- REMBRANT-01
- Acronym
- REMBRANT
- Status last verified
- Feb 2026
- First submitted
- 5 Jan 2026
- Last updated
- 27 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data (IPD) underlying the results of this study will be shared upon reasonable request after publication of the primary results. Shared data will be de-identified to protect participant privacy. Requests will be reviewed by the study investigators and access will be granted for scientifically valid research proposals, subject to appropriate data use agreements and applicable ethical and legal approvals.
Publications
No publications available at this time.
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reduction of Muscle Catabolism Through Brain Activation in Burn Patients (REMBRANT)
- ClinicalTrials.gov ID
- NCT07435402
- Acronym / sponsor ID
- REMBRANT / REMBRANT-01
- Conditions
- Burns - Multiple, Critical Illness, Muscle Weakness
- Keywords
- extensive burn injury, skeletal muscle wasting, brain activation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Charles University, Czech RepublicUniversity, hospital or other
- Collaborators
- Masaryk University
- Study start
- 1 May 2026 (estimated)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 30 Jun 2030 (estimated)
- First posted
- 27 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with extensive burn injuries frequently develop severe skeletal muscle wasting and weakness as part of critical illness-related myopathy and neuropathy. This condition delays ventilator weaning, prolongs intensive care unit (ICU) and hospital stay, and contributes to long-term functional impairment and reduced quality of life. In burn patients, muscle loss is particularly pronounced during the early post-injury phase and is associated with mitochondrial dysfunction and altered neuromuscular signaling.
Effective strategies to prevent muscle catabolism in critically ill burn patients remain limited. Although early active rehabilitation is beneficial, many patients are unable to participate due to deep sedation, mechanical ventilation, or clinical instability. Therefore, innovative rehabilitation approaches applicable during the acute phase of critical illness are needed.
The REMBRANT (REduction of Muscle catabolism through BRAin activation in burn patieNTs) study is a single-center, randomized, controlled, open-label clinical trial evaluating whether a multimodal brain-activating rehabilitation strategy can attenuate skeletal muscle loss in adult patients with severe burns. Thirty patients with burns involving more than 30% of total body surface area who require invasive mechanical ventilation and prolonged sedation will be randomized in a 1:1 ratio to standard care or an intervention group.
Both groups will receive standardized burn treatment and conventional rehabilitation. The intervention group will additionally receive the Burn-Bundle Extended Rehabilitation Program, combining inhalational isoflurane sedation with functional proprioceptive stimulation, repetitive transcranial magnetic stimulation, and virtual reality-assisted rehabilitation when clinically feasible.
The primary outcome is change in skeletal muscle mass and strength. Secondary outcomes include ICU length of stay, ventilator-free days, mitochondrial function, and health-related quality of life.
Detailed description
Critically ill patients with extensive burn injuries are at exceptionally high risk of developing profound skeletal muscle wasting and weakness as part of critical illness-related myopathy and neuropathy (CRIMYNE). This condition represents a major determinant of short- and long-term outcomes, contributing to delayed ventilator weaning, prolonged intensive care unit (ICU) and hospital length of stay, impaired rehabilitation, and persistent functional disability after discharge. In patients with large burns, muscle loss is particularly rapid and severe during the early post-injury phase, frequently exceeding 1 kg of lean body mass per day, and is accompanied by mitochondrial dysfunction, systemic inflammation, altered myokine signaling, and neurodegenerative changes affecting central, peripheral, and autonomic nervous systems.
Despite extensive research, effective preventive or therapeutic strategies to limit skeletal muscle catabolism in critically ill burn patients remain limited. Nutritional optimization, pharmacological interventions, and passive or assisted rehabilitation techniques have demonstrated minimal or inconsistent benefit. Active rehabilitation remains the only proven preventive approach; however, a substantial proportion of burn patients are unable to participate due to deep sedation, invasive mechanical ventilation, hemodynamic instability, prone positioning, unstable fractures, or the extent and severity of burn injuries. Consequently, there is a critical unmet need for rehabilitation strategies that can be applied safely and effectively during the early acute phase of critical illness.
Recent advances in neurorehabilitation suggest that activation of central motor pathways may exert anti-catabolic effects on skeletal muscle even in immobilized or unconscious patients. Functional proprioceptive stimulation (illusory movements induced by focal muscle vibration) activates cortical motor areas and has been shown to promote antidegenerative processes within the nervous system and skeletal muscle. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique capable of modulating cortical excitability and enhancing neuroplasticity, with established safety and efficacy in various neurological and movement disorders. Virtual reality (VR)-assisted rehabilitation provides immersive multisensory stimulation and may enhance motor network activation and engagement in conscious patients.
Sedation strategy is another critical determinant of neurological and functional outcomes in critically ill patients. Conventional intravenous sedatives, including propofol, dexmedetomidine, and benzodiazepines, are associated with adverse effects such as hemodynamic instability, prolonged awakening, delirium, drug accumulation, and potential neurodegenerative effects. Inhalational sedation with isoflurane represents a validated alternative that allows predictable awakening, preservation of spontaneous breathing, reduced opioid requirements, and potentially improved neurocognitive outcomes. Its use may facilitate daily sedation interruptions and early rehabilitation strategies in ICU patients.
The REMBRANT (REduction of Muscle catabolism through BRAin activation in burn patieNTs) study is a single-center, randomized, controlled, open-label clinical trial designed to evaluate whether a multimodal brain-activating rehabilitation strategy can attenuate skeletal muscle catabolism and improve functional outcomes in adult patients with extensive burn injuries. The study aims to integrate optimized sedation with innovative neurorehabilitation techniques to target the central mechanisms contributing to muscle wasting in critical illness.
A total of 30 adult patients with burns involving more than 30% of total body surface area (TBSA), admitted to the ICU and expected to require invasive mechanical ventilation and continuous sedation for at least seven days, will be enrolled. Participants will be randomized in a 1:1 ratio to either a control group receiving standard care or an intervention group receiving the Burn-Bundle Extended Rehabilitation Program. The study is conducted at a single specialized burn center to ensure standardized implementation of complex interventions and uniform data acquisition.
Both groups will receive standardized burn care and conventional rehabilitation according to institutional protocols. The control group will be sedated using standard intravenous sedatives, including propofol and/or dexmedetomidine. The intervention group will undergo inhalational sedation with isoflurane for the required duration of sedation. In addition, the intervention group will receive the Burn-Bundle Extended Rehabilitation Program, consisting of functional proprioceptive stimulation, repetitive transcranial magnetic stimulation, and virtual reality-assisted rehabilitation when consciousness allows. Functional proprioceptive stimulation will be applied twice daily during the early acute phase after burn injury, while rTMS will be administered once daily to potentiate cortical activation. Virtual reality-based interventions will be introduced in conscious patients as part of semi-active rehabilitation.
The primary objective of the study is to evaluate the effect of the intervention on skeletal muscle quantity and functional status during hospitalization and after discharge. Skeletal muscle mass and body composition will be assessed using dual-energy X-ray absorptiometry (DEXA), ultrasound measurement of the rectus femoris muscle, and anthropometric assessments. Functional status will be evaluated using standardized functional tests, including the Medical Research Council (MRC) sum score.
Secondary objectives include assessment of ICU length of stay, ventilator-free days, cognitive recovery, and quality of life. Quality of life will be evaluated using the EQ-5D-5L questionnaire at discharge and during follow-up visits at 3 and 6 months after hospital discharge. Cognitive recovery will be assessed using standardized clinical evaluations appropriate for critically ill patients.
A key mechanistic component of the study involves detailed metabolic and molecular analyses of skeletal muscle. Muscle biopsies obtained during routine surgical procedures will be used to assess mitochondrial bioenergetics using high-resolution respirometry. Parameters of mitochondrial function, including oxidative phosphorylation capacity, fatty acid oxidation, and respiratory control ratios, will be analyzed to determine the impact of the intervention on muscle energy metabolism.
In parallel, circulating and intramuscular myokine profiles will be analyzed using multiplex immunoassays. Selected myokines involved in muscle metabolism, inflammation, and neuro-muscular signaling will be measured in plasma samples and muscle biopsies at predefined time points during hospitalization. These analyses aim to elucidate the molecular mechanisms underlying muscle catabolism and recovery and to identify potential biomarkers associated with response to rehabilitation.
The study will be conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and applicable local regulatory requirements. Written informed consent will be obtained from all participants or their legally authorized representatives prior to study inclusion. The study protocol has been approved by the local Ethics Committee.
By combining optimized inhalational sedation with innovative neurorehabilitation techniques applicable during the acute phase of critical illness, the REMBRANT study aims to establish a novel therapeutic approach to limit skeletal muscle wasting in critically ill burn patients. The results of this study may provide important insights into central mechanisms of muscle catabolism and recovery and contribute to improved short-term clinical outcomes as well as long-term functional recovery and quality of life in this vulnerable patient population.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants will be randomly assigned in a 1:1 ratio to one of two parallel groups: a control group receiving standard burn care and conventional rehabilitation with intravenous sedation, and an intervention group receiving standard burn care plus the Burn-Bundle Extended Rehabilitation Program, including inhalational isoflurane sedation and multimodal neurorehabilitation. Participants will remain in their assigned group for the duration of the study.
| Arm | Type | Receives |
|---|---|---|
| Propofol Group | No intervention | –Standard Burn Care with Intravenous Sedation |
| Isoflurane Group | Experimental | Other: Burn-Bundle Extended Rehabilitation Program, Drug: Isoflurane Inhalational Sedation, Device: Functional Proprioceptive Stimulation, Device: Neurorehabilitation TechniquesBurn-Bundle Extended Rehabilitation Program with Isoflurane Sedation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults aged 18 years or older
- Severe burn injury involving more than 30% of total body surface area (TBSA)
- Admission to the intensive care unit
- Expected need for invasive mechanical ventilation and continuous sedation for at least 7 days
- Ability to obtain written informed consent from the patient or a legally authorized representative
Key exclusion criteria (5 listed)
- Pre-existing severe neuromuscular or neurodegenerative disease
- Known contraindication to inhalational sedation with isoflurane
- Pregnancy or breastfeeding
- Participation in another interventional clinical trial that could interfere with the study outcomes
- Any condition that, in the opinion of the investigator, would make participation in the study unsafe or interfere with protocol adherence
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Burn-Bundle Extended Rehabilitation ProgramA multimodal brain-activating rehabilitation program consisting of inhalational isoflurane sedation combined with functional proprioceptive stimulation, repetitive transcranial magnetic stimulation, and virtual reality-assisted rehabilitation when consciousness allows, applied during the acute phase after severe burn injury. | Other | Isoflurane Group |
| Isoflurane Inhalational SedationSedation with inhaled isoflurane administered via an anesthetic conserving device during invasive mechanical ventilation, used as an alternative to standard intravenous sedatives. | Drug | Isoflurane Group |
| Functional Proprioceptive StimulationIllusory movements induced by focal vibration of muscle attachments to activate central motor pathways, applied twice daily during the acute phase of critical illness. | Device | Isoflurane Group |
| Neurorehabilitation TechniquesNon-invasive neurorehabilitation techniques including repetitive transcranial magnetic stimulation and virtual reality-assisted rehabilitation applied to enhance cortical activation and neuroplasticity in critically ill burn patients when clinically feasible. | Device | Isoflurane Group |
Primary outcome
Change in skeletal muscle mass assessed by dual-energy X-ray absorptiometry (DEXA)
Time frame: From baseline (within first 7 days after ICU admission) up to 24 weeks.
Change in lean body mass measured by dual-energy X-ray absorptiometry. Lean mass is reported in kilograms (kg).
Change in rectus femoris muscle thickness assessed by ultrasound
Time frame: From baseline (day 10 after injury) to day 30 after injury
Change in rectus femoris muscle thickness measured by ultrasound. Muscle thickness is reported in millimeters (mm).
Change in muscle strength assessed by the Medical Research Council (MRC) Sum Score
Time frame: From baseline (within first 7 days after ICU admission) up to 24 weeks.
Muscle strength assessed using the Medical Research Council (MRC) Sum Score. The MRC Sum Score ranges from 0 to 60, with higher scores indicating greater muscle strength.
8 secondary outcomes
Intensive care unit length of stay
Time frame: From ICU admission up to 24 weeks.
Ventilator-free days
Time frame: From ICU admission up to 24 weeks.
Mitochondrial oxidative phosphorylation capacity
Time frame: Days 10, 20, and 30 after injury
Myokine profiles
Time frame: During hospitalization (days 10, 20, and 30 after injury).
Cognitive function assessed using the Montreal Cognitive Assessment (MoCA). The MoCA score ranges from 0 to 30, with higher scores indicating better cognitive performance.
Time frame: At hospital discharge, 3 months, and 6 months after discharge.
Health-related quality of life assessed by the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L)
Time frame: At hospital discharge, 3 months, and 6 months after discharge
Fatty acid oxidation capacity of skeletal muscle mitochondria
Time frame: Days 10, 20, and 30 after injury
Mitochondrial respiratory control ratio
Time frame: Days 10, 20, and 30 after injury
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
- BackgroundNo publications available at this time.
- General information about the study and study siteLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Individual participant data (IPD) underlying the results of this study will be shared upon reasonable request after publication of the primary results. Shared data will be de-identified to protect participant privacy. Requests will be reviewed by the study investigators and access will be granted for scientifically valid research proposals, subject to appropriate data use agreements and applicable ethical and legal approvals.
Related trials for Burns - Multiple
Enrolling by invitationObservational study
Evaluating the Accuracy of Multiple Blood Tests to Diagnose Sepsis in Adult Burn Patients
Sepsis - to Reduce Mortality in the Intensive Care Unit, Burns Involving 20% or More of Body Surface
Not yet recruiting
Response of Muscle Mechanical Properties to Early Multi-angles Isometric Exercises in Acute Burn Patients
Burns
Not yet recruitingObservational study
Project PHOENIX: Molecular Signatures of Burn Pit Exposure
Burn Pit Exposure, Airborne Hazard Exposure
Not yet recruitingObservational study
Surgical Critical Care Initiative (SC2i) Tissue and Data Acquisition Protocol (TDAP) in Burn Patients Improving the Robustness and Generalizability of Post-burn Sepsis Prediction With the Post-Burn Sepsis Digital Twin. Group 1
Sepsis, Burn Injury
Not yet recruitingObservational study
TDAP in Burn Patients (Group 2)
Sepsis, Burn Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Bohumil Bakalář, MD, PhD principal investigator
University Hospital Kralovske Vinohrady Praha Czech Republic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Burn-Bundle Extended Rehabilitation Program, Isoflurane Inhalational Sedation and Functional Proprioceptive Stimulation in people with Burns - Multiple and Critical Illness, run by Charles University, Czech Republic at 1 site in Czechia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bohumil Bakalář, MD, PhD (+420 728816095, bohumil.bakalar@lf3.cuni.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in skeletal muscle mass assessed by dual-energy X-ray absorptiometry (DEXA) (time frame: From baseline (within first 7 days after ICU admission) up to 24 weeks.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07435402, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.